Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  cannabis  company  feb  february  marketwired feb  marketwired february  marketwired  new  today  weight 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Mon, 27 Feb 2017 10:53:50 EST

Copyright: Copyright: (C) Marketwired
 



Dr. Lisa A. Fortier Joins TissueGen's Scientific Advisory Board

Mon, 27 Feb 2017 10:00:00 EST

Expert in Application of Biologics for Cartilage Repair and Tendinosis Joins Team Pioneering Advances in Drug Delivery, Nerve Regeneration and Tissue Engineering




Health Advance Inc. Announces $7 Million Financing Agreement with GHS Investments

Mon, 27 Feb 2017 09:47:49 EST

LAS VEGAS, NV--(Marketwired - Feb 27, 2017) -  Health Advance Inc. (the "Company" or "Health Advance") (OTC PINK: HADV) is pleased to announce that the Company has entered into an Equity Financing Agreement ("Agreement") with GHS Investments LLC, a Nevada limited liability company (Hereinafter referred to as "GHS"). The Agreement allows Health Advance to access up to $7 million in capital over the next 24 months. This financing will also allow the Company to continue its growth through acquisitions and will allow the Company to effectively execute its business plan and growth model.




Advantis Corp. Striking Agreement to Triple Amstercan Packaging Efficiency

Mon, 27 Feb 2017 09:28:00 EST

NEWPORT BEACH, CA--(Marketwired - Feb 27, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is currently negotiating with N2Pack in order to get a more efficient Amstercan packaging machine. N2Pack is the manufacturer that currently supplies canning equipment for Advantis.




Nutritional High Comments on the Cannabis Industry Landscape and Regulation

Mon, 27 Feb 2017 09:17:22 EST

TORONTO, ONTARIO--(Marketwired - Feb. 27, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) wishes to comment on recent statements made by some of the members of US Presidential Administration in regards to US Federal Government's stance on the cannabis industry in the US.




Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Mon, 27 Feb 2017 09:00:00 EST

LOS ANGELES, CA--(Marketwired - Feb 27, 2017) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2016.




Amedica Announces Results of Independent Femoral Head Wear Testing

Mon, 27 Feb 2017 09:00:00 EST

SALT LAKE CITY, UT--(Marketwired - Feb 27, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that Researchers from the Department of Orthopaedic Surgery of Tokyo Medical University (Shinjuku-ku, Tokyo, Japan) led by Professor Kengo Yamamoto MD PhD recently completed a five million cycle (Mc) comparative hip simulator study examining the wear behavior of an advanced highly cross-linked and vitamin E stabilized polyethylene (E1® Zimmer-Biomet, Warsaw, IN, USA) against two different types of ceramic femoral heads -- MC2®silicon nitride (Amedica Corporation, Salt Lake City, UT, USA) and BIOLOX®delta (CeramTec, Plochingen, Germany). BIOLOX®delta is currently considered the "gold standard" for ceramic femoral head materials. While the polyethylene wear loss induced by both types of ceramic heads was extremely small (< 0.60 mg/Mc), mean wear associated with MC2®silicon nitride heads was approximately 15% lower than the BIOLOX®delta components.




Organigram Completes Investigation and Provides Update on Compensation Policy

Mon, 27 Feb 2017 08:30:00 EST

MONCTON, NEW BRUNSWICK--(Marketwired - Feb. 27, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (the "Company") announces that it has completed the investigation related to a recent contamination issue which resulted in voluntary recalls of medical cannabis products produced by the Company.




BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion

Mon, 27 Feb 2017 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC --(Marketwired - February 27, 2017) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the "Offering") of 5,416,667 units of the Company (the "Units") at a price of C$0.24 per Unit for aggregate gross proceeds of C$1,300,000. Under the terms of the Offering, each Unit shall consist of one common share in the capital of the Company (a "Common Share") and one-half of a Common Share purchase warrant (a "Warrant"). Each Warrant will be exercisable for one Common Share at an exercise price of C$0.35. The Warrants will be exercisable for 24 months following the date of closing of the Offering. The Offering is subject to the approval of the TSX Venture Exchange and other customary closing conditions.




ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017

Mon, 27 Feb 2017 08:00:00 EST

ORY-2001 Reduces Lymphocyte Egress and Demyelination in Experimental Autoimmune Encephalomyelitis; Data highlights the Epigenetic Axis in Multiple Sclerosis




Lion Biotechnologies to Present at Upcoming Investor Conferences in March

Mon, 27 Feb 2017 08:00:00 EST

SAN CARLOS, CA--(Marketwired - February 27, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that company management will present a corporate update at two investor conferences in March:




Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference

Mon, 27 Feb 2017 08:00:00 EST

PHILADELPHIA, PA--(Marketwired - Feb 27, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at 4:40 p.m. EST at the Boston Marriott Copley Place.




Lexaria Receives Notice of its First Patent to be Granted in Australia for Cannabinoid Infused Edibles

Mon, 27 Feb 2017 08:00:00 EST

KELOWNA, BC--(Marketwired - February 27, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") is pleased to announce it has received a Notice of Acceptance from the Australian Patent Office that Lexaria's Australian patent application 2015274698 has been accepted with a patent issuance date expected in June, 2017. This establishes Lexaria's first successful acceptance for patent issuance outside of the USA, in what the Company expects will be a series of successful international patent awards.




ProPhase Labs Reports Financial Results for the Year Ended December 31, 2016

Mon, 27 Feb 2017 08:00:00 EST

DOYLESTOWN, PA--(Marketwired - February 27, 2017) - ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $21.0 million for the year ended December 31, 2016 as compared to net sales of $20.6 million for the year ended December 31, 2015. The Company incurred a net loss for the year ended December 31, 2016, of $2.9 million, or $0.17 per share, compared to a net loss of $3.6 million, or $0.22 per share, for the year ended December 31, 2015.




VANC Pharmaceuticals Launches New OTC Laxative Product Sennace

Mon, 27 Feb 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 27, 2017) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:VANC)(OTCQB:NUVPD), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets announces the launch of a new OTC laxative to the market place. Sennace represents another in a series of OTC products launched and to be launched by VANC.




Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical

Mon, 27 Feb 2017 07:30:00 EST

Novel Hepcidin Inhibitor Addressing High Medical Need in Anemia of Chronic Disease




Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada

Mon, 27 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - Feb 27, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada ("NRC") for the worldwide right to anti-CEACAM6 antibody 2A3 for oncology applications.




Diet Doc Offers Weight Loss And Weight Maintenance Alternatives To The Dangerous Original hCG Diet

Mon, 27 Feb 2017 01:00:00 EST

PHOENIX, AZ--(Marketwired - February 27, 2017) - Even after following a consistent weight loss process and achieving positive results, many obese and overweight individuals experience weight regain. Weight maintenance depends on a variety of factors, including genetics, personal behavior, and the environment. Following a regular diet and reducing daily caloric intake also has a significant effect. Behavioral therapy may be provided to those continuously struggling with weight regain. The stability of body weight can also be increased by avoiding harmful behaviors like emotional eating, late-night snacking, consuming excessive amounts of sugar, binge eating, and relapsing into an inactive lifestyle.




Dr. Timothy Greco Now Offers Volbella(R) in Philadelphia

Sat, 25 Feb 2017 09:00:00 EST

By adding Juvederm Volbella(R) to his Philadelphia-area practice, Dr. Timothy Greco kicked off 2017 with more options than ever for patients looking for nonsurgical cosmetic options for the face




ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016

Fri, 24 Feb 2017 13:40:04 EST

BARCELONA, SPAIN and CAMBRIDGE, MA--(Marketwired - February 24, 2017) - Oryzon Genomics (MAD: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fourth quarter of 2016 and provided an update on the Company's recent developments.




Acasti Pharma Grants Incentive Stock and Options

Fri, 24 Feb 2017 12:33:08 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 24, 2017) - Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST)(TSX VENTURE:ACST), today announced the grant of an aggregate of 100,000 incentive stock options under the Corporation's Stock Option Plan for two new independent directors who joined Acasti's Board of Directors at the last Annual and Special Meeting of Shareholders, held in July 2016. Each option will vest over a period of 30 months and will entitle its holder to purchase one common share of Acasti at a price of CDN $1.65, until February 24, 2027.




Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

Fri, 24 Feb 2017 11:30:00 EST

TTI-621's Half-life and Receptor Occupancy Significantly Increased with Weekly Dosing




Cannabis Science Announces Update on Proposed DPI Inhalation Device, CBD Infused Pain Patch, and Extends Praise for President Trump's Support of Medical Cannabis, Nationwide

Fri, 24 Feb 2017 11:06:27 EST

IRVINE, CA--(Marketwired - Feb 24, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce updates on the proposed self-medicating DPI Inhalation Device for Asthma/COPD and our Cannabinoid infused pain patch. The Company is working on the final packaging for the Cannabinoid-based Pain Patches and will roll out to partner dispensaries in the Los Angeles area very soon, joining the existing Cannabis Science product line.




ALGAE DYNAMICS CORP Announces Research Agreement With University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer

Fri, 24 Feb 2017 09:30:00 EST

TORONTO, ON--(Marketwired - Feb 24, 2017) - ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company"), a development stage company focused on the commercialization of its proprietary BioSilo® cultivation and extraction system for the growth of algae strains for use in the food and health supplement industry, today announced a research agreement with the University of Waterloo to perform fundamental research on cannabis oil and its constituents in the context of the development and treatment of cancers of the colorectum, pancreas, breast and prostate. The Sponsored Research Agreement is entitled "Studies on botanical oils from Algae Dynamics".




Aphria Announces Closing of Bought Deal Financing

Fri, 24 Feb 2017 09:20:58 EST

Announces Additional Investment in Kalytera




Canadian Cannabis Task Force Cites Impaired Driving as a Serious Issue Demanding Immediate Attention -- CFN Media

Fri, 24 Feb 2017 09:02:28 EST

SEATTLE, WA--(Marketwired - Feb 24, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing the Canadian Cannabis Task Force's recommendations for addressing impaired driving, and Cannabix Technologies' (OTC PINK: BLOZF) position in the emerging cannabis breathalyzer market.




EnWave Announces 2017 First Quarter Consolidated Interim Financial Results

Fri, 24 Feb 2017 09:00:00 EST

VANCOUVER, BC--(Marketwired - February 24, 2017) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") today reported the Company's consolidated interim financial results for the first quarter ended December 31, 2016. The Company reported consolidated revenue of $3,467,000, and a consolidated net loss of $618,000 for the first quarter of fiscal year 2017.




Tetra Bio-Pharma Grants Stock Options

Fri, 24 Feb 2017 08:30:00 EST

OTTAWA, ONTARIO--(Marketwired - Feb. 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) announces that on February 23, 2017, in accordance with the Company's stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 750,000 incentive stock options ("options") to its officers and directors of the Company. Each option, vesting immediately upon grant, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.70 per share until February 23, 2022. The options and any common shares issued upon exercise thereof will be subject to a four month resale restriction from the date of grant.




CannaRoyalty Strategic Partner Natural Ventures Completes Successful Commercial Launch in Puerto Rico Medical Cannabis Market

Fri, 24 Feb 2017 08:14:06 EST

OTTAWA, ONTARIO--(Marketwired - Feb. 24, 2017) - CannaRoyalty Corp. (CSE:CRZ)(CSE:CRZ.CN)(OTCQB:CNNRF) ("CannaRoyalty") is pleased to announce that its strategic partner Natural Ventures PR, LLC ("Natural Ventures"), Puerto Rico's largest licensed cultivation and manufacturing medical cannabis company with an indoor growing facility of 100,000 square feet, has successfully harvested its first crop and has begun selling cannabis products to licensed medical dispensaries.




First Half 2017 Operational Update

Fri, 24 Feb 2017 02:13:12 EST

SYDNEY, AUSTRALIA--(Marketwired - Feb 24, 2017) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)




Dr. Nishant Rao of Diet Doc Finds Unexpected Similarities Between the Sirtfood Diet and Doctor-Supervised Weight Loss

Fri, 24 Feb 2017 01:00:00 EST

CHARLESTON, WV--(Marketwired - February 24, 2017) - The Sirtfood Diet focuses on consuming foods which may interact with a type of protein called, Sirtuins. The primary foods that contain this protein include chocolate, red wine, kale, blueberries, citrus, prawns, and salmon as well as green juices. The diet itself is limited to 1000 calories for each of the first three days, then the diet increases to 1500 calories per day. Dr. Nishant Rao -- Medical Director of Diet Doc's national medical weight loss program advises dieters who are looking to lose weight on the Sirtfood Diet that, "Most of the initial weight loss during the first three days is going to be glycogen weight (stored carbohydrates + water), not actual fat loss." Dr. Rao continues, "Also, there is very little research on the actual impact that these foods have on weight loss when you take their calorie counts out of the equation."




A Federal Crackdown on Recreational Cannabis Could Cost Industry Billions and Thousands of Jobs

Thu, 23 Feb 2017 18:07:12 EST

WASHINGTON, DC--(Marketwired - February 23, 2017) - New Frontier Data, the authority in business intelligence for the cannabis industry, for the past two years has been monitoring the top 10 trends that could affect the market and a cannabis unfriendly administration has been among those. Today White House Press Secretary Sean Spicer suggested that those on the recreational side of the industry could see "greater enforcement" from the Department of Justice. If the federal government decided to crack down on the adult use side, this year alone, it could jeopardize $2.5 billion in projected revenue and $8.6 billion by 2020.




NutraFuels, Inc. (NTFU) Announces Further Steps for Initiation of Clinical Trials with the Company's Product Line of Oral Spray Nutraceuticals

Thu, 23 Feb 2017 17:30:46 EST

COCONUT CREEK, FL--(Marketwired - February 23, 2017) - NutraFuels, Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced that the company as part of the implementation of initiation of clinical studies on the company's product line of oral spray nutraceuticals has announced the appointment of Kenneth Duchin, Ph.D. as Vice-President Clinical Development and the agreement with Palm Beach Research to conduct clinical studies.




CloudHealth Genomics Presents their Unique Market Strategy and ImmuneSeq(TM) Panel for both Cancer and Non-Cancer Immunotherapies

Thu, 23 Feb 2017 14:06:03 EST

BOSTON, MA and SHANGHAI, CHINA--(Marketwired - Feb 23, 2017) - CloudHealth Genomics, Ltd., a leading genomics-based precision medicine solutions provider in China, presented data today on their unique business model, using open and disruptive innovation as a market strategy for precision medicine, wellness and longevity. In addition, data was presented as a by-product of the model, ImmuneSeq panel at the Cambridge Healthtech Institute's Third Annual Commercialization of Molecular Diagnostics, part of the 24th International Molecular Medicine Tri-Conference held in San Francisco, CA. ImmuneSeq is able to monitor immune responses, like T-cell activities for both cancer and non-cancer immunotherapies.




iData Research Publishes Article on U.S. Orthopedic Biomaterials Market: Shift in Competitive Strategy

Thu, 23 Feb 2017 13:20:51 EST

Cellular allografts currently comprise the fastest growing segment of the orthopedic biomaterials market in the U.S.; the high average selling price of cellular allografts provides incentives for new players to enter the market




Ogilvy CommonHealth Worldwide's Michael Zilligen to speak at the Advertising and Promotion Regulatory Affairs Conference

Thu, 23 Feb 2017 12:15:42 EST

PARSIPPANY, NJ--(Marketwired - Feb 23, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Michael Zilligen, president of Ogilvy CommonHealth Payer Marketing and Ogilvy Healthworld Payer Marketing, has been selected to speak at the Advertising and Promotion Regulatory Affairs Conference taking place February 23 and 24 in Washington, DC.




Somnia Announces Winner of Sixth Annual CRNA of the Year Award

Thu, 23 Feb 2017 10:00:00 EST

Randy Graybeal of Washington State-based PRMC Selected




Ogilvy CommonHealth Worldwide's Baranello and Vidal Inducted Into the Medical Advertising Hall of Fame's Future Famers Program

Thu, 23 Feb 2017 09:46:54 EST

PARSIPPANY, NJ--(Marketwired - Feb 23, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Jigna Baranello, VP, account group supervisor, and Ana Maria Vidal, account executive, were both named to the Medical Advertising Hall of Fame's (MAHF) fifth annual Future Famers Program at last night's awards dinner held at the Pierre Hotel in New York City.




Thérapeutique Knight annonce un changement à son conseil d'administration

Thu, 23 Feb 2017 09:21:28 EST

MONTRÉAL, QUÉBEC--(Marketwired - 23 fév. 2017) - Thérapeutique Knight inc. (TSX:GUD) («?Knight?») a annoncé aujourd'hui (i) la démission de Ed Schutter et (ii) la nomination de Dre. Sarit Assouline au conseil d'administration de Knight. «?Je remercie Ed pour sa contribution remarquable à Knight depuis qu'il avait joint nos rangs début 2015, a déclaré Jonathan Ross Goodman, chef de la direction de Knight. Nous accueillons, pour le remplacer dans notre équipe de direction, Dre. Sarit Assouline, hématologue à l'Hôpital général juif et professeure associée de médecine et d'oncologie à l'Université McGill. Dre. Assouline est une clinicienne qui a de nombreuses publications à son actif; c'est un ajout à la diligence scientifique de Knight, au moment où nous obtenons des licences pour des médicaments innovants qui améliorent la vie des patients?».




Knight Therapeutics Inc. Announces Board Change

Thu, 23 Feb 2017 09:21:11 EST

MONTREAL, QUÉBEC--(Marketwired - Feb. 23, 2017) - Knight Therapeutics Inc. (TSX:GUD) ("Knight") announced today (i) the resignation of Ed Schutter and (ii) the appointment Dr. Sarit Assouline to Knight's Board of Directors. "I thank Ed for his meaningful contributions to Knight since joining in early 2015," said Jonathan Ross Goodman, CEO of Knight. "In his place, we welcome Dr. Sarit Assouline, a Hematologist at the Jewish General Hospital and associate professor of Medicine and Oncology at McGill University, to our leadership team. Dr. Assouline is a well published clinician adding another level of scientific diligence to Knight as we in-license innovative pharmaceuticals that touch the lives of patients."




Agritek Holdings, Inc. Announces Plans For Additional Cultivation Property With Licenses In Colorado On Heels of Receiving Listing In First Proposed Cannabis Exchange Fund (ETF)

Thu, 23 Feb 2017 09:19:42 EST

LOS ANGELES, CA--(Marketwired - Feb 23, 2017) - Agritek Holdings, Inc. (OTC PINK: AGTK), a leader in compassionate care technology and agricultural solutions for the recreational cannabis industry, today announced that the Company has entered into negotiations to purchase an additional thirty-five (35) acre property located in Pueblo county which has already been approved and received licenses for cultivation. The new property with existing structures will be managed on behalf of Agritek by licensed cultivators with a strong track record within the state. Additional plans for a manufacturing facility and recreational license to work in cooperation with the recently announced and completed purchase of the eighty (80) acre parcel and proposed cannabis farm for the medicinal and recreational sector located in Pueblo, Colorado will also be under the same operational agreement.




First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals

Thu, 23 Feb 2017 09:15:00 EST

NEW YORK, NY--(Marketwired - February 23, 2017) - PharmaCyte Biotech (OTCQB: PMCB) will join GW Pharmaceuticals, Abbott Laboratories and 66 other publicly traded companies in what could be the first ever cannabis exchange-traded fund (ETF) -- the Emerging AgroSphere ETF. One week ago, ETF Managers Group, headquartered in Summit, New Jersey, filed an initial registration statement with the SEC to become the first of its kind in the ETF industry (https://www.sec.gov/Archives/edgar/data/1467831/000114420417009539/v459698_485apos.htm).




The Life Sciences Report Examines How the RXi-MirImmune Merger Is Aiming to Unlock Value Through Groundbreaking Technology

Thu, 23 Feb 2017 09:00:00 EST

SAN FRANCISCO, CA--(Marketwired - February 23, 2017) - RXi Pharmaceuticals Corp.'s (NASDAQ: RXII) proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort.




American Green Smart Vending System Unveiled to the Public on April 19th in Las Vegas at the Largest Machine Industry Event (NAMA) in America

Thu, 23 Feb 2017 08:30:00 EST

PHOENIX, AZ--(Marketwired - Feb 23, 2017) - American Green, Inc. (OTC PINK: ERBB) is excited to announce that its proprietary verified vending system which includes the American Green Machine (AGM) or 'The Ultimate AGM' will make its public debut at 'The One Show' (http://www.namaoneshow.org) in Las Vegas, April 19-21. The show, organized by the National Automatic Merchandising Association (NAMA) is the premier industry event and includes the largest manufacturers and vendors in the country.




Golden Leaf Launches New Golden Gold Label Reserve Product Line

Thu, 23 Feb 2017 08:30:00 EST

TORONTO, ON--(Marketwired - February 23, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce the introduction of its new Golden Gold Label Reserve product line, new Private Stash brand strain flavors, and branded Golden full flower pre-roll joints. Launching in dispensaries across Oregon, Gold Label Reserve and the new Private Stash strain varieties are targeted at medical and recreational customers looking for pure solvent-free and high potency cannabis oil products. The Golden pre-roll joints focus on meeting growing consumer demand for high quality pre-rolled joints.




Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients

Thu, 23 Feb 2017 08:05:00 EST

Alveolar Macrophages treated with JBT-101 demonstrated reduced levels of key pro-inflammatory cytokines, TNF- alpha and IL-6




MapR Joins Susan G. Komen(R) in the Mission to end Breast Cancer

Thu, 23 Feb 2017 07:00:00 EST

SAN JOSE, CA--(Marketwired - Feb 23, 2017) - MapR Technologies, Inc., the provider of the first and only converged data platform, is advising Susan G. Komen as the breast cancer organization convenes its second national conference with subject matter experts working to leverage Big Data for breast cancer care.




CannaGrow Holdings Announces the Reduction of Outstanding Common Shares of its Capital Stock

Thu, 23 Feb 2017 06:30:00 EST

GREENWOOD VILLAGE, CO--(Marketwired - Feb 23, 2017) - CannaGrow Holdings, Inc. (OTC PINK: CGRW) -- a Liaison and Consultant providing turnkey solutions to licensed growers, announces the cancellation of 799,861 shares of common stock reducing the Issued and Outstanding Share Count to 101,273,573. The Float has remained unchanged at 25,762,901 since August of 2014.




Diet Doc Reminds Consumers that the hCG Diet is not a Viable Weight Loss Strategy

Thu, 23 Feb 2017 01:00:00 EST

WESTON, WV--(Marketwired - February 23, 2017) - The physicians and researchers at Diet Doc medical weight loss are urging consumers to choose wisely when it comes to weight loss strategies this year. Certain diets are gaining popularity due to an enormous internet presence, which leaves little room for proven, researched based weight loss strategies. This can lead many individuals to make unsafe dietary choices simply because a fad has allegedly produced satisfactory results for other dieters. The hGG diet is a prime example of this. Produced during pregnancy, the human chorionic gonadotropin hormone (hCG) is purported to stimulate weight loss in conjunction with a calorie restrictive diet plan (only 500 calories per day are to be consumed). Supporters claim that HCG injections, drops or tablets target and eliminate long-stored fat reserves within the body. Over the past few years, the marketing and promotion of the hCG diet for weight loss have grown astronomically on the internet and the vast majority of the information on hCG and its corresponding products offered online are designed to confuse and make profit from an unknowing public. The truth, is that the medical industry has never supported the hCG diet. In fact, since its emergence in the 1950s, it still has yet to be deemed effective, or safe by any reputable medical organization.




Cleveland BioLabs Reports 2016 Financial Results and Development Progress

Wed, 22 Feb 2017 16:15:00 EST

BUFFALO, NY--(Marketwired - Feb 22, 2017) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2016.




Preparing for ICH-GCP E6(R2) at Investigator Sites, New Xtalks Webinar Presented by Intralinks

Wed, 22 Feb 2017 15:39:53 EST

Live Session on March 15, 2017 Includes Q&A with GCP Inspector and Discussion on Investigator Site Perspectives




Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers

Wed, 22 Feb 2017 15:13:29 EST

MISSION VIEJO, CA--(Marketwired - February 22, 2017) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today the initiation of a phase 1 study with its lead compound AEOL 10150. The phase 1 study is an open-label, single center, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of an escalating single dose of AEOL 10150 administered by subcutaneous injection in healthy subjects.




Fresenius Lead Dialysis Machine Market Fueled by Popularity of Home-Hemodialysis Treatment

Wed, 22 Feb 2017 14:00:00 EST

The market for hemodialysis machines is comprised of in-center machines and home hemodialysis machines; the market will exceed a value of $360 million by 2023




Présentation de Neptune à la 29e conférence annuelle Growth Stock de ROTH Capital Partners

Wed, 22 Feb 2017 13:54:58 EST

LAVAL, QUÉBEC--(Marketwired - 22 fév. 2017) - Neptune Technologies & Bioressources inc. (« Neptune » ou la « Société ») (NASDAQ:NEPT)(TSX:NEPT) a annoncé que Jim Hamilton, son président et chef de la direction, donnera une présentation le lundi 13 mars à 14 h 30 (HP) dans le cadre de la 29e conférence annuelle ROTH qui se tiendra au Ritz-Carlton de Laguna Niguel, en Californie. Pour en savoir plus ou pour planifier une rencontre individuelle avec un membre de la direction, veuillez communiquer avec votre représentant ROTH au 1-800-933-6830 ou par courriel à conference@roth.com.




Neptune to Present at ROTH Capital Partners 29th Annual Growth Stock Conference

Wed, 22 Feb 2017 13:54:13 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 22, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NEPT), announced that Jim Hamilton, CEO of the Corporation, will present at the 29th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel, CA on Monday, March 13 at 2:30pm PT. For more information about the conference or to schedule a one-on-one meeting with management, please contact your ROTH representative at 1-800-933-6830 or via e-mail conference@roth.com.




Harvest One Announces Closing of $25 Million Financing Related to Acquisition of ACMPR Licensed Medical Cannabis Producer and Swiss Medical Cannabis-Based Health Products Company

Wed, 22 Feb 2017 12:06:42 EST

TORONTO, ONTARIO--(Marketwired - Feb. 22, 2017) -




Ogilvy CommonHealth Worldwide's Nora Tsivgas to present at the 8th Hub and SPP Model Optimization Event

Wed, 22 Feb 2017 11:14:36 EST

PARSIPPANY, NJ--(Marketwired - Feb 22, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Nora Tsivgas, SVP, access services strategies at Ogilvy CommonHealth Payer Marketing, will lead a workshop during the Hub and SPP Model Optimization conference in Philadelphia, PA, on Thursday, February, 23.




HealthMax Group, Inc. interview on KCAA radio Morning Show

Wed, 22 Feb 2017 10:30:00 EST

HICKSVILLE, NY--(Marketwired - Feb 22, 2017) - WRAPmail, Inc. (OTC PINK: WRAP) (www.wrapmail.com) is pleased to announce that an interview with the principals of HealthMax Group, Inc. will air live Friday, February 24, 2017, at 6:30 am PST on the KCAA morning show "On the Brink."




NutraFuels, Inc. (NTFU) Prepares to Conduct Clinical Studies on the Company's Product Line of Oral Spray Nutraceuticals beginning with the Company's Sleep Support Oral Spray Containing CBD (Cannabidiol)

Wed, 22 Feb 2017 10:00:00 EST

COCONUT CREEK, FL--(Marketwired - February 22, 2017) - NutraFuels, Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced that the company is in the process of implementing clinical efficacy studies on the company's product line of oral spray nutraceuticals beginning with the company's Sleep Support oral spray containing CBD (Cannabidiol).




3DX Industries completes development on proprietary product for use in the $6.7+ Billion Legalized Marijuana Industry

Wed, 22 Feb 2017 09:29:00 EST

SEATTLE WA--(Marketwired - Feb 22, 2017) - 3DX Industries Inc. (OTC: DDDX) 3DX Industries Inc., (the "Company" or "3DX") is pleased to announce it has completed the development and design of a new and innovative product used for recovering excess heat from high energy grow lights. The product captures excess heat energy at the individual, grow light source; before it can raise the overall grow room temperature. The captured heat energy can then either be exhausted outside of the facility or routed to areas within the facility or nearby that require heat. Initial engineering studies are indicating a reduction in overall air conditioning electrical load by up to 30%. 




Freedom Leaf, Inc. (OTC PINK: FRLF) Filings Posts Major Improvement in Operating Results For The Six Months Ended December 31, 2016

Wed, 22 Feb 2017 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Feb 22, 2017) - Freedom Leaf, Inc. (OTC PINK: FRLF)




Laguna Blends CEO Interview and Article Discussing Expansion -- CFN Media

Wed, 22 Feb 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Feb 22, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article and exclusive CEO video interview detailing Laguna Blends Inc.'s (OTC PINK: LAGBF) recent corporate developments and the company's focus on acquisition and incubation of smaller companies.




Maple Leaf Capitalizing on Legal Cannabis in the U.S. and Canada -- CFN Media

Wed, 22 Feb 2017 09:00:00 EST

SEATTLE, WA--(Marketwired - Feb 22, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article and executive video interview covering Maple Leaf Green World Inc.'s (TSX VENTURE: MGW) (OTCQB: MGWFF) efforts in both the Canadian and the U.S. cannabis markets.




eWellness to Present at the 2017 Wall Street Conference in Boca Raton on March 1, 2017

Wed, 22 Feb 2017 08:50:00 EST

CULVER CITY, CA--(Marketwired - Feb 22, 2017) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first telehealth company for physical therapy to offer insurance reimbursable remotely monitored physical therapy (PT) treatments. The Company will be presenting at the Wall Street Conference in Boca Raton Florida at 10:00am March 1, 2017. www.wallstconference.com




New Frontier Data: U.S. Cannabis Market Creates 283,422 Jobs by 2020

Wed, 22 Feb 2017 08:38:32 EST

WASHINGTON, DC--(Marketwired - February 22, 2017) - New Frontier Data, the authority in business intelligence for the cannabis industry, continues to find evidence demonstrating the legal cannabis is one of the fastest growing industries in the U.S., and examines its growth in its upcoming annual report, The Cannabis Industry Annual Report: 2017 Legal Marijuana Outlook. New Frontier Data projects that by 2020 the legal cannabis market will create more than a quarter million jobs for American workers.




Global Small Caps Initiates Coverage on Nutra Pharma

Wed, 22 Feb 2017 08:30:00 EST

CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-AwayT in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.




Sipp Industries in Partnership with Sleeping Giant Brewing Embarks on Formulation of New Cannabidiol Infused Beer

Wed, 22 Feb 2017 08:30:00 EST

As Sales for "Major Hemp Brown Ale" Take Off, Company Prepares for Second Quarter Launch of Next Select Premium Brewing Innovation




Apexian Pharmaceutical CEO, Steve Carchedi, to present at Drexel University's Guest Healthcare Lecture Series

Wed, 22 Feb 2017 08:04:05 EST

PHILADELPHIA, PA--(Marketwired - February 22, 2017) - Apexian Pharmaceuticals, a clinical stage biotechnology company focused on developing novel compounds to treat cancer, today announced that its CEO would present at Drexel University's Healthcare Guest Lecture Series (LeBow.Drexel.edu/event/healthcare) to be held at Gerri C. LeBow Hall (GHall), room 722, 3220 Market St, Philadelphia, PA 19104 on the campus of Drexel University at 4:30 PM EST on March 1, 2017.




BioVie Submits Additional Information to FDA for BIV201 Clinical Trial in Ascites Patients

Wed, 22 Feb 2017 08:00:00 EST

BEVERLY, MA--(Marketwired - February 22, 2017) - BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by BioVie last month.




Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome

Wed, 22 Feb 2017 08:00:00 EST

LEXINGTON, MA--(Marketwired - Feb 22, 2017) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has developed and launched the Aldeyra Registry for Sjögren-Larsson Syndrome (SLS), a rare inborn error of aldehyde metabolism that is characterized by severe skin and neurological disease. The Aldeyra Registry for SLS is designed to unite SLS patients worldwide, and to raise awareness of the significant physical challenges associated with the disease.




NuGene International Appoints S. David Ollie As Vice President, Sales

Wed, 22 Feb 2017 08:00:00 EST

Veteran Sales Executive in both Medical and Aesthetic areas of Dermatology and Plastic Surgery Industries




Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada

Wed, 22 Feb 2017 08:00:00 EST

ATLANTA, GEORGIA and MONTREAL, QUEBEC--(Marketwired - Feb. 22, 2017) - Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, and Knight Therapeutics Inc. (TSX:GUD) (Knight), a leading Canadian specialty pharmaceutical company, today announced that Knight's New Drug Submission (NDS) for ILUVIEN® has been accepted for review by Health Canada. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is Alimera's sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.




Alimera Sciences et Thérapeutique Knight annoncent le dépôt de présentation de drogue nouvelle pour Iluvien(R) au Canada

Wed, 22 Feb 2017 08:00:00 EST

ATLANTA, GEORGIA et MONTRÉAL, QUÉBEC--(Marketwired - 22 fév. 2017) - Alimera Sciences, Inc. (NASDAQ:ALIM) («?Alimera?»), chef de file en recherche, développement et commercialisation de produits pharmaceutiques ophtalmologiques sur ordonnance, et Thérapeutique Knight inc. (TSX:GUD) («?Knight?»), société pharmaceutique spécialisée et chef de file au Canada, ont annoncé aujourd'hui que Santé Canada a accepté de procéder à l'évaluation de la présentation de drogue nouvelle (PDN) de Knight pour ILUVIEN®. ILUVIEN (implant intravitréen d'acétonide de fluocinolone) de 0,19 mg is est un implant intravitréen à libération prolongée d'Alimera homologué aux États-Unis pour le traitement de l'odème maculaire diabétique («?OMD?») auprès des patients qui ont reçu préalablement un traitement aux corticostéroïdes sans augmentation significative clinique de la pression intraoculaire.




ICTV Brands, Inc. Provides Update on Successful and Upcoming Television Home Shopping Promotions

Wed, 22 Feb 2017 08:00:00 EST

WAYNE, PA--(Marketwired - Feb 22, 2017) -  ICTV Brands, Inc. (OTCQX: ICTV), (CSE: ITV)




Vinergy Resources/MJ BioPharma to Acquire 65% of Health Canada and FDA Licensed Laboratory to Pursue Drug Testing and Dosage of CBDs, THC and Terpenes

Wed, 22 Feb 2017 08:00:00 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 22, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent ("LOI") to acquire 65% of Biolennia Laboratories Inc. (the "Laboratory").




FutureLand (FUTL) Signs Agreement Tied to Revenue Producing Acquisitions and Access to Capital -- Landmark Deal Sets Up Strong Future in Cannabis Sector

Wed, 22 Feb 2017 08:00:00 EST

DENVER, CO--(Marketwired - Feb 22, 2017) - FutureLand Corp. (OTCQB: FUTL), a dynamic growth company in the cannabis sector, announced today that it has signed an agreement with Greenleaf Holdings, LLC ("Greenleaf"). This exclusive agreement will provide FutureLand with the ability to make a series of strategic acquisitions, furthering its quest to become a major player in the cannabis industry, named as the fastest growing industry in the U.S.




30% of Drug Companies Compensate HCPs Differently for International vs. Domestic Air Travel

Wed, 22 Feb 2017 07:48:00 EST

Pharma Companies Establish FMV Travel Policies for Healthcare Providers




Adgero Biopharmaceuticals Holdings Inc. Announces $2.0 Million Investment from Strategic Asian Investor

Wed, 22 Feb 2017 07:30:00 EST

PRINCETON, NJ--(Marketwired - February 22, 2017) - Adgero Biopharmaceuticals Holdings, Inc. ("Adgero" or the "Company"), a privately-held biopharmaceutical company leveraging its late stage photodynamic therapy ("PDT") platform for the treatment of serious oncology indications, announced today that it has received a $2.0 million investment from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ("FDZJ"), located in Shanghai, China.




Nutritional High Provides Update on Pueblo, Colorado Operations

Wed, 22 Feb 2017 07:30:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 22, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to provide the following update on its cannabis extraction business in Pueblo, Colorado.




30Mil CAD$ Investment in European Centre of Cancer Immunotherapy

Wed, 22 Feb 2017 07:30:00 EST

TORONTO, ON--(Marketwired - Feb 22, 2017) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology ("HIO") has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership ("KEN POLAND") in support of the European Centre for Cancer Immunotherapy ("ECCI").




InCrowd Debuts MicroQual, First Qualitative Micro Research Solution for Life Sciences & Healthcare

Wed, 22 Feb 2017 07:00:00 EST

By Allowing Completion of Healthcare Stakeholder Interviews in a Fraction of the Time, MicroQual Delivers Richer, More Comprehensive Market Insights, Sourced with Validated Experts




Revive Therapeutics Announces Term Sheet with InMed Pharmaceuticals for the Discovery and Development of Cannabinoid-Based Therapy Targeting Kidney Diseases

Wed, 22 Feb 2017 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Feb. 22, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), today announced the Company has entered into a term sheet agreement with InMed Pharmaceuticals Inc. ("InMed") for the discovery and development of cannabinoid-based therapies targeting kidney diseases.




Southwest Cannabis Conference & Expo Returns to Texas for Largest Event Yet

Wed, 22 Feb 2017 06:00:00 EST

DALLAS, TX--(Marketwired - Feb 22, 2017) - The Southwest Cannabis Conference & Expo (http://SWCCExpo.com) is returning to Texas for its second annual event. After setting new records at the last event in Phoenix -- where more than 150 exhibitors showcased their goods to over 6,800 attendees -- the SWCC Expo is looking to set new records in 2017.




Model N to Present Global Pricing and Tendering Strategies at Pharma Pricing and Market Access Congress 2017

Wed, 22 Feb 2017 03:00:00 EST

Join Model N to learn industry trends and best practices for optimal global pricing




Diet Doc Provides Customized And Healthy Weight Loss Alternatives To Starvation-Based hCG Diet

Wed, 22 Feb 2017 01:00:00 EST

PHOENIX, AZ--(Marketwired - February 22, 2017) - When it comes to weight loss, some of the most important factors include genetics, general health, daily behavior and physical activities. Based on research, dieting is the most important component that affects weight gain or weight loss. By improving eating behavior, for instance, one can dramatically affect their weight. This is why emotional eating, binge eating and other common dietary abnormalities can have long-term effects of body weight. Effective weight loss generally involves losing more calories than you gain. Because one pound of weight is equivalent to 3,500 calories, one needs to reduce caloric intake by 500-1000 calories per day in order to lose 1-2 pounds per week. However, this type of extreme dieting is often starvation-based and therefore risky.




SafetyChain Software's February FSMA Fridays Session to Focus on Listeria Guidance from FDA

Tue, 21 Feb 2017 17:43:38 EST

SAN RAFAEL, CA--(Marketwired - February 21, 2017) - SafetyChain Software, the leading innovator of food safety & quality management solutions, is pleased to announce the February 2017 topic for its popular FSMA Fridays series with Dr. David Acheson and The Acheson Group team - Listeria Guidance from the FDA.




Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children's Hospital of Philadelphia

Tue, 21 Feb 2017 17:27:25 EST

PHILADELPHIA, PA--(Marketwired - Feb 21, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children's Hospital of Philadelphia (CHOP). The amendment to the existing agreement with CHOP grants the Company options for long-term exclusive access to certain data and samples from the CAG biobank and certain discoveries in rare and orphan diseases. Aevi Genomics has also renewed its Sponsored Research Agreement (SRA) with CHOP. The extension of the SRA marks the third renewal of sponsored research at CHOP, jointly focused on the genetics of rare and orphan pediatric disease. 




Acasti Pharma annonce la clôture du placement public d'unités et du placement privé de débentures convertibles et de bons de souscription simultanés

Tue, 21 Feb 2017 17:26:51 EST

LAVAL, QUÉBEC--(Marketwired - 21 fév. 2017) -




Acasti Pharma Announces Closings of Concurrent Public Offering of Units and Private Placement of Convertible Debentures and Warrants

Tue, 21 Feb 2017 17:26:06 EST

LAVAL, QUÉBEC--(Marketwired - Feb. 21, 2017) -




Nutritional High Announces an Update Regarding Its Agreements to Acquire Cultivation and Production Licenses in Henderson, Nevada

Tue, 21 Feb 2017 15:42:04 EST

TORONTO, ONTARIO--(Marketwired - Feb. 21, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to provide an update on its acquisition of provisional cultivation and production licenses (the "Licenses") in Henderson, Nevada and a real estate property (the "Property") to which the Licenses are attached.




Progressive Care Issues Update on Recent Trading Volume

Tue, 21 Feb 2017 14:30:23 EST

MIAMI, FL--(Marketwired - February 21, 2017) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, issues updated information regarding recent market trading volume.




AIDS Services Foundation Orange County Takes Major Strides in Prep Education

Tue, 21 Feb 2017 14:10:26 EST

The Non-Profit Hires Ryan Assaf as its First Pre-Exposure Prophylaxis (PrEP) Navigator




BioAegis Therapeutics Announces Addition of Leading Critical Care Nephrologist to its Clinical Advisory Board

Tue, 21 Feb 2017 13:01:44 EST

Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials




hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate

Tue, 21 Feb 2017 12:28:10 EST

Vaccine could protect against diseases such as Zika and Malaria; hVIVO's joint venture investment with SEEK in a new company, Imutex, was formed to accelerate the development of this vaccine




AssistRx to Offer its iAssist Solution on the Accenture Intelligent Patient Service Exchange

Tue, 21 Feb 2017 11:30:00 EST

ORLANDO, FL--(Marketwired - Feb 21, 2017) - AssistRx (ARx), the leading enterprise technology platform focused on specialty and highly managed medications, today announced it will make available its iAssist solution on the Accenture Intelligent Patient Service Exchange, a digital marketplace of third-party technology solutions available to life sciences companies to enhance patient support and improve the overall patient treatment experience.




Christy D. Jones Named Product Liability Attorney of the Year by Benchmark Litigation

Tue, 21 Feb 2017 11:17:20 EST

RIDGELAND, MS--(Marketwired - February 21, 2017) - Butler Snow is pleased to announce that Christy D. Jones has been named Product Liability Attorney of the year by Benchmark Litigation, a leading national law publication. Jones was honored at the Benchmark Litigation 2017 Awards held Feb. 16, in New York.




Taglich Brothers Initiates Coverage on Aytu Bioscience, Inc.

Tue, 21 Feb 2017 10:04:43 EST

NEW YORK, NY--(Marketwired - February 21, 2017) - Taglich Brothers, Inc. announces it initiated coverage of AYTU Bioscience, Inc.




Vaportronix Seeks to Raise Capital through Fundable to Rapidly Expand Business Operations and Growth in the United States for Premium Portable Vaporizer Smartphone Case

Tue, 21 Feb 2017 10:00:00 EST

$99, patented, one-of-a-kind, sleek phone case and vaporizer that's always with you and always charged




Advantis Corp. Begins Distribution of Ground Breaking New Cannabis Products for Pain Relief

Tue, 21 Feb 2017 09:37:30 EST

NEWPORT BEACH, CA--(Marketwired - Feb 21, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) begins distribution of topical cannabis roll-on and Tinctures to treat pain conditions.




Emerald Health Accelerates Expansion with $13 Million Capital Raise -- CFN Media

Tue, 21 Feb 2017 09:15:00 EST

SEATTLE, WA--(Marketwired - Feb 21, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article discussing Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) recent financing and the company's plans for expansion of its facilities.




Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer

Tue, 21 Feb 2017 09:05:00 EST

CITY OF INDUSTRY, CA--(Marketwired - Feb 21, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Seymour Fein, M.D., as Chief Medical Officer